Compare AbbVie Inc (ABBV) vs Dollar General Corp. (DG) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Dollar General (DG) trades at $126.59, down 0.69% on the day, with strong technical momentum indicated by bullish moving averages and oversold RSI conditions. The company demonstrates consistent earnings beats with Q1 2026 EPS of $2.00 exceeding expectations of $1.89, while maintaining solid profitability metrics including 18.91% ROE. Recent cash flow trends show improvement with 2025 net cash flow of $395 million, and the balance sheet reflects declining debt-to-asset ratios from 22.73% to 20.03% year-over-year.

The outlook remains positive with analyst consensus favoring Buy ratings (52%) and a $128.45 price target offering modest upside. Key opportunities include consumer trade-down benefits and margin improvement, while risks involve competition from Walmart and Amazon, market saturation concerns, and ongoing cost pressures. The stock presents a value proposition with attractive P/S (0.65) and P/E (17.91) multiples relative to historical norms.